266 completed, 30 unknown, 15 terminated, 11 active not recruiting. 345 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 345 | Completed 266, Unknown 30, Terminated 15, Active not recruiting 11, Recruiting 9, Not yet recruiting 8, Withdrawn 4, Enrolling by invitation 1, Suspended 1 |
Follow Influenza, Human: new trials by email Literature Review of Influenza, Human trials Research Report on Influenza, Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| How Healthy Adults Respond to the Nasal Flu Vaccine FluMist (Live Attenuated Influenza Vaccine) - Mucosal Immune Response to Influenza Vaccination | Phase 4 | Not yet recruiting | University of Alabama at Birmingham | 20 | 2026-12-01 | 2026-10-13 |
| Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine - Pneumococcal Polysaccharide Vaccine, Influenza Vaccines | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 1278 | 2026-11-01 | 2026-10-21 |
| Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore High-dose influenza vaccine, Standard-dose influenza vaccine - Influenza | Phase 4 | Not yet recruiting | Tan Tock Seng Hospital | 150 | 2026-11-01 | 2026-10-20 |
| SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial) LAIV FLUMIST - Influenza (Healthy Volunteers) | Phase 4 | Not yet recruiting | McMaster University | 966 | 2026-10-15 | 2026-07-31 |
| A Study of Updated mRNA Seasonal Influenza Vaccines mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine - Seasonal Influenza | Phase 4 | Not yet recruiting | ModernaTX, Inc. | 200 | 2026-10-15 | 2026-10-20 |
| A Study to Evaluate the Immune Responses of Subunit Influenza Vaccine in Healthy Adults Group A, Group B - Influenza | Phase 4 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 138 | 2026-10-10 | 2026-10-16 |
| A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) Anflu®, Vaxigrip® - Influenza | Phase 4 | Not yet recruiting | Sinovac Biotech Co., Ltd | 150 | 2026-10-01 | 2026-09-21 |
| Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults Standard dose influenza vaccine, MF59 adjuvanted influenza vaccine, High dose influenza vaccine - Influenza Vaccination, Older Adults (65 Years and Older) | Phase 4 | Recruiting | Korea University Guro Hospital | 180 | 2026-09-21 | 2026-09-24 |
| Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) - COVID-19, Influenza | Phase 4 | Not yet recruiting | Tor Biering-Sørensen | 410000 | 2026-09-01 | 2026-08-27 |
| Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients Influenza Vaccine Group, Pneumococcal Vaccine Group - Influenza and Pneumonia | Phase 4 | Not yet recruiting | Jiangsu Province Centers for Disease Control and Prevention | 7000 | 2026-06-15 | 2026-06-11 |
| A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine LAIV, Placebo - Influenza | Phase 4 | Enrolling by invitation | Changchun BCHT Biotechnology Co. | 200 | 2026-04-09 | 2026-04-22 |
| Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses Flu Vaccine, Biological samples - Volunteers, Flu Vaccine | Phase 4 | Active not recruiting | Centre Hospitalier Universitaire de Saint Etienne | 30 | 2025-12-05 | 2025-12-30 |
| Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions Influenza vaccination - Myocardial Infarction, Decompensated Chronic Heart Failure | Phase 4 | Recruiting | Wroclaw Medical University | 400 | 2025-11-12 | 2026-06-01 |
| Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine - COVID -19, COVID - 19 | Phase 4 | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 54 | 2025-11-12 | 2026-10-28 |
| Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults Standard-Dose Influenza Vaccine, MF59-Adjuvanted Influenza Vaccine, High-Dose Influenza Vaccine - Influenza, Influenza Vaccines | Phase 4 | Completed | Korea University Guro Hospital | 121 | 2025-10-25 | 2026-09-04 |
| Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine LAIV - Influenza | Phase 4 | Active not recruiting | Jiangsu Province Centers for Disease Control and Prevention | 60 | 2025-10-12 | 2025-11-18 |
| The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study Live attenuated influenza vaccine, Placebo nasal spray, recombinant hemagglutinin influenza vaccine - Influenza | Phase 4 | Active not recruiting | The University of Hong Kong | 600 | 2025-10-01 | 2026-05-15 |
| Woodsmoke Exposure, Influenza Infection, and Nasal Immunity LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection - Smoke Exposure, Influenza | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 112 | 2025-09-26 | 2026-04-30 |
| Characterizing the Human Airway Immune Response to FluMist Vaccination FluMist, inactivated influenza vaccine, bronchoscopy - Healthy Young Adults, Influenza Vaccines | Phase 4 | Recruiting | Washington University School of Medicine | 30 | 2025-09-09 | 2025-09-17 |
| Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine - Influenza | Phase 4 | Completed | Tor Biering-Sørensen | 466320 | 2025-05-31 | 2025-09-12 |
Showing 20 of 345. Sign in to see all of them.
Respiratory Tract Infections (10) · Orthomyxoviridae Infections (9) · COVID-19 (7) · Virus Diseases (7) · Pneumonia (6) · Heart Failure (5) · Common Cold (4) · HIV Infections (4) · Infections (4) · Pneumonia, Pneumococcal (4) · Arthritis, Rheumatoid (3) · Drug-Related Side Effects and Adverse Reactions (3) · Fever (3) · Injection Site Reaction (3)
RNA Virus Infections (344) · Respiratory Tract Diseases (343) · Infections (341) · Virus Diseases (338) · Orthomyxoviridae Infections (336) · Respiratory Tract Infections (335) · Pathological Conditions, Signs and Symptoms (19) · Lung Diseases (17) · Pathologic Processes (14) · Urogenital Diseases (13) · Immune System Diseases (12) · Bacterial Infections and Mycoses (11) · Bacterial Infections (10) · Pneumonia (10) · Cardiovascular Diseases (9)
Influenza Vaccines (135) · Oseltamivir (25) · FluMist (24) · vaxigrip (17) · fluad vaccine (10) · Vaccines (9) · fluarix (7) · FluBlok (5) · Fluzone High-Dose (5) · Acetaminophen (4) · Inflexal V (4) · Poliovirus Vaccine, Inactivated (4) · arepanrix (4) · baloxavir (3) · 2019-nCoV Vaccine mRNA-1273 (2)
Sanofi Pasteur, a Sanofi Company (32) · Stanford University (20) · GlaxoSmithKline (12) · MedImmune LLC (12) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Sinovac Biotech Co., Ltd (10) · Duke University (9) · Seqirus (9) · McMaster University (8) · Jiangsu Province Centers for Disease Control and Prevention (7) · Korea University Guro Hospital (7) · The University of Hong Kong (7) · Centers for Disease Control and Prevention (6) · Adimmune Corporation (5) · Emory University (5)
United States (141) · China (40) · Canada (24) · United Kingdom (14) · South Korea (9) · France (7) · Russia (7) · Belgium (6) · Denmark (6) · Taiwan (6) · Germany (5) · Hong Kong (5) · Hungary (5) · Italy (5) · Poland (5)
Cornelia Dekker, MD (12) · Stephen Quake, PhD (8) · Xiaosong He, PhD (8) · Mark Davis, PhD (6) · Ann Arvin, MD (5) · Cornelia L Dekker, MD (5) · Garry Nolan, PhD (5) · Harry Greenberg, MD (5) · Hee Jin Cheong, MD, PhD (5) · David Scheifele, MD (4)
PMID 28963118, PMID 29706550, PMID 21378375, PMID 26069949, PMID 10439494, PMID 10471173, PMID 10628898, PMID 10934667, PMID 11744606, PMID 12915495, PMID 13998, PMID 14706961, PMID 15195237, PMID 15694506, PMID 16140685, PMID 16220095, PMID 16372666, PMID 16831228, PMID 17167134, PMID 17167135, PMID 17395338, PMID 17698577, PMID 18401289, PMID 18425905, PMID 18507871, PMID 18522501, PMID 18559644, PMID 19361304, PMID 19637952, PMID 19776407, PMID 19909082, PMID 20018364, PMID 20215608, PMID 20386004, PMID 20532100, PMID 20632888, PMID 20815736, PMID 21028955, PMID 21060780, PMID 21103330, PMID 21106443, PMID 21130194, PMID 21148531, PMID 21178654, PMID 21540203, PMID 21788422, PMID 21806398, PMID 21820477, PMID 21844547, PMID 21859696
U19AI057229 (15), U19AI090019 (4), 2009 (2), 2015 (2), 2005 (1), 2008 (1), 2018 (1), 2025 (1), 272201400005C-P00019-9999-4 (1), N01AO50042 (1), R01AI041050 (1), R01AI129709 (1), R01AI132348 (1), R01ES036209 (1), R01HL149944 (1)